Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUNDTRACK-F1
jRCT2031240501Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of surovatamig and rituximab in follicular lymphoma (FL) (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of surovatamig plus rituximab, Recommended Phase III dose and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
surovatamigrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2031240501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240501.